A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Prostate

• Publication date

  2012-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/pros.21493PMID 22670265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer

  2014cited by this paper
• A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression

  2009cited by this paper
• Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer

  2009cited by this paper
• Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.

  2008cited by this paper
• Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

  2008cited by this paper
• Cell‐Surface labeling and internalization by a fluorescent inhibitor of prostate‐specific membrane antigen

  2008influential reference
• Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics.

  2008influential reference
• Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

  2008cited by this paper
• Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.

  2007cited by this paper
• Progress in the discovery and development of glutamate carboxypeptidase II inhibitors.

  2007cited by this paper
• Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

  2007cited by this paper
• Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.

  2007cited by this paper
• Molecular markers of prostate cancer.

  2006cited by this paper
• Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography.

  2006cited by this paper
• Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates.

  2006cited by this paper
• Microfluidic system for studying the interaction of nanoparticles and microparticles with cells.

  2005cited by this paper
• Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer

  2005cited by this paper
• Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

  2005cited by this paper
• Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

  2005cited by this paper
• High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen

  2005cited by this paper
• Future therapies in hormone-refractory prostate cancer.

  2005cited by this paper
• Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography.

  2005cited by this paper
• Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival

  2004cited by this paper
• In vivo cancer targeting and imaging with semiconductor quantum dots

  2004cited by this paper
• Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

  2003cited by this paper
• 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).

  2002cited by this paper
• Ins and outs of clinical trials with peptide-based vaccines.

  2002cited by this paper
• Anti‐tumor effects of toxins targeted to the prostate specific membrane antigen

  2002cited by this paper
• Radiolabeled peptides in the diagnosis and therapy of oncological diseases.

  2002cited by this paper
• Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

  2002cited by this paper
• A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

  2001cited by this paper
• Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase

  2001cited by this paper
• Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity

  2001cited by this paper
• Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.

  2001cited by this paper
• Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

  1998cited by this paper
• Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.

  1996cited by this paper
• Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids

  1995cited by this paper
• Expression of the prostate-specific membrane antigen.

  1994cited by this paper
• Ligand-induced desensitization of 125I-epidermal growth factor internalization.

  1989cited by this paper

• Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer

  2025cites this paper
• A small-molecule pretargeting approach for PSMA-targeted conjugates.

  2025cites this paper
• PSMA-targeted SMART molecules outfitted with SN38.

  2024cites this paper
• Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone

  2024cites this paper
• Preclinical Evaluation of a PSMA Aptamer-Based Bifunctional PET and Fluorescent Probe.

  2024cites this paper
• A PSMA-targeted doxorubicin small-molecule drug conjugate.

  2024cites this paper
• Technetium(I) carbonyl complexes for nuclear medicine: Coordination-chemical aspect

  2023cites this paper
• PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.

  2023cites this paper
• Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects

  2023cites this paper
• Therapeutic potential of targeting mirnas to prostate cancer tumors: using psma as an active target

  2022cites this paper
• Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors

  2022cites this paper
• A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer

  2022cites this paper
• Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells.

  2021cites this paper
• Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends

  2021cites this paper
• Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer

  2021cites this paper
• Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

  2021cites this paper
• Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications

  2020cites this paper
• Radiopharmaceutical therapy in cancer: clinical advances and challenges

  2020cites this paper
• Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.

  2019cites this paper
• Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy

  2019cites this paper
• Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor.

  2017cites this paper
• 177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors : The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice

  2017cites this paper
• 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice

  2017cites this paper
• Metal-Based PSMA Radioligands

  2017influential citation
• Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.

  2016cites this paper
• Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.

  2016cites this paper
• Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.

  2016cites this paper
• A method to determine the mode of binding for GCPII inhibitors using bio-layer interferometry

  2016cites this paper
• Structure − Activity Relationship of 18 F ‐ Labeled Phosphoramidate Peptidomimetic Prostate-Speci fi c Membrane Antigen ( PSMA )-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer

  2016cites this paper
• Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

  2016cites this paper
• Prostate-specific membrane antigen as a target for cancer imaging and therapy.

  2015cites this paper
• Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.

  2015cites this paper
• PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.

  2015cites this paper
• Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer

  2015cites this paper
• A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.

  2015cites this paper
• BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)

  2015cites this paper
• 64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer

  2014cites this paper
• Biochemical characterization of prostate‐specific membrane antigen from canine prostate carcinoma cells

  2014cites this paper
• PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance

  2013cites this paper
• A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.

  2013cites this paper
• Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.

  2013cites this paper
• Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

  2013cites this paper
• PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

  2013cites this paper
• Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.

  2012cites this paper
• DEVELOPMENT OF PSMA-TARGETED SPECT IMAGING AGENTS FOR PROSTATE CANCER

  2012cites this paper